Literature DB >> 24935815

Use of in situ hybridization for HPV in head and neck tumors: experience from a national reference laboratory.

Benjamin L Witt1, Daniel J Albertson, Margaret G Coppin, Christian F Horrocks, Melissa Post, H Evin Gulbahce.   

Abstract

The human papillomavirus (HPV) status of head and neck squamous cell carcinomas (SCCs) is a frequent request for Anatomic Pathology labs. However, prognostic value of HPV status is limited to identification of high risk HPV in oropharyngeal SCCs. The purpose of this study is to investigate the ordering practices of in situ hybridization (ISH) for HPV in head and neck tissues at our national reference laboratory. All testing orders for low risk, high risk, and combined low and high risk HPV-ISH tests requested at ARUP Laboratories between January 2010 and November 2013 had their results reviewed and were grouped by anatomic location of the tested tissue. The H&E and HPV-ISH slides from a sample of the most recent 123 tests were reviewed by two pathologists. A total of 1,128 HPV-ISH tests were ordered during the study period. Testing for combined low and high risk HPV was the most commonly ordered test. The positivity rate for high risk HPV was highest in oropharyngeal tissues. 49 of 123 reviewed cases had testing requested on non-malignant tissue, 11 of which were non-neoplastic. Unnecessary HPV-ISH ordering is prevalent in head and neck tissues. Dual testing for low and high risk HPV, frequent testing outside of the oropharynx, and testing non-neoplastic tissues appear to be common practices.

Entities:  

Mesh:

Year:  2014        PMID: 24935815      PMCID: PMC4382492          DOI: 10.1007/s12105-014-0549-1

Source DB:  PubMed          Journal:  Head Neck Pathol        ISSN: 1936-055X


  21 in total

1.  High-risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma.

Authors:  Odey C Ukpo; John J Flanagan; Xiao-Jun Ma; Yuling Luo; Wade L Thorstad; James S Lewis
Journal:  Am J Surg Pathol       Date:  2011-09       Impact factor: 6.394

Review 2.  Exploring biomarkers in head and neck cancer.

Authors:  Corey J Langer
Journal:  Cancer       Date:  2012-01-26       Impact factor: 6.860

Review 3.  The sinonasal tract: another potential "hot spot" for carcinomas with transcriptionally-active human papillomavirus.

Authors:  James S Lewis; William H Westra; Lester D R Thompson; Leon Barnes; Antonio Cardesa; Jennifer L Hunt; Michelle D Williams; Pieter J Slootweg; Asterios Triantafyllou; Julia A Woolgar; Kenneth O Devaney; Alessandra Rinaldo; Alfio Ferlito
Journal:  Head Neck Pathol       Date:  2013-12-14

Review 4.  Rationale for cost-effective laboratory medicine.

Authors:  A Robinson
Journal:  Clin Microbiol Rev       Date:  1994-04       Impact factor: 26.132

5.  Human papillomavirus and rising oropharyngeal cancer incidence in the United States.

Authors:  Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

Review 6.  p16 Immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma.

Authors:  James S Lewis
Journal:  Head Neck Pathol       Date:  2012-07-03

7.  Treatment outcomes and prognostic factors, including human papillomavirus, for sinonasal undifferentiated carcinoma: a retrospective review.

Authors:  Stacey T Gray; Marc W Herr; Rosh K V Sethi; Gillian Diercks; Linda Lee; William Curry; Annie Chan; John Clark; Eric H Holbrook; James Rocco; Peter M Sadow; Derrick T Lin
Journal:  Head Neck       Date:  2014-04-30       Impact factor: 3.147

8.  Prevalence and significance of human papillomavirus in oral tongue cancer: the Mayo Clinic experience.

Authors:  Xin-Hua Liang; Jason Lewis; Robert Foote; David Smith; Deepak Kademani
Journal:  J Oral Maxillofac Surg       Date:  2008-09       Impact factor: 1.895

9.  Association of human papilloma virus with atypical and malignant oral papillary lesions.

Authors:  Christina McCord; Jing Xu; Wei Xu; Xin Qiu; Nidal Muhanna; Jonathan Irish; Iona Leong; Richard John McComb; Bayardo Perez-Ordonez; Grace Bradley
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2014-02-14

10.  Detection and significance of human papillomavirus, CDKN2A(p16) and CDKN1A(p21) expression in squamous cell carcinoma of the larynx.

Authors:  Rebecca D Chernock; Xiaowei Wang; Ge Gao; James S Lewis; Qin Zhang; Wade L Thorstad; Samir K El-Mofty
Journal:  Mod Pathol       Date:  2012-09-21       Impact factor: 7.842

View more
  4 in total

1.  The prognostic role of sex, race, and human papillomavirus in oropharyngeal and nonoropharyngeal head and neck squamous cell cancer.

Authors:  Carole Fakhry; William H Westra; Steven J Wang; Annemieke van Zante; Yuehan Zhang; Eleni Rettig; Linda X Yin; William R Ryan; Patrick K Ha; Alicia Wentz; Wayne Koch; Jeremy D Richmon; David W Eisele; Gypsyamber D'Souza
Journal:  Cancer       Date:  2017-02-27       Impact factor: 6.860

2.  Prognostic role of human papilloma virus status in hypopharyngeal squamous cell carcinoma.

Authors:  Deborah C Marshall; Derek D Kao; Richard Bakst; Sonam Sharma; Rocco Ferrandino; Kenneth Rosenzweig; Juan Wisnivesky; Keith Sigel
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-08-11

Review 3.  Current and future techniques for human papilloma virus (HPV) testing in oropharyngeal squamous cell carcinoma.

Authors:  Ali Qureishi; Thomas Mawby; Lisa Fraser; Ketan A Shah; Henrik Møller; Stuart Winter
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-03-11       Impact factor: 2.503

4.  Human papillomavirus infection in patients with laryngeal carcinoma.

Authors:  Ozlem Onerci Celebi; Ebru Sener; Sefik Hosal; Mustafa Cengiz; Ibrahim Gullu; Gaye Guler Tezel
Journal:  BMC Cancer       Date:  2018-10-20       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.